NTRBNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends January 31
NutriBand Inc.
Financials through Q2 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 4, 2026
$6.00−0.22 (-3.54%)
Close on Oct 19, 2026
- Market cap
- $72.94M
- P/E (TTM)
- –
- Dividend yield
- –
NutriBand Inc. revenue by segment
By business segment
| Revenue | Q2 27 | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4P Therapeutics [Member] | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Pocono Pharmaceuticals [Member] | – | – | $400.71K | $346.06K | $622.45K | $667.43K | $642.38K | $645.80K | $442.83K | $408.53K | $524.61K | $427.84K | – | – |
By product or service
| Revenue | Q2 27 | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sale of Goods [Member] | $437.51K | $433.40K | $400.71K | $346.06K | $614.92K | $667.43K | $642.38K | $645.80K | $442.83K | $408.53K | $524.61K | $427.84K | 100.0% | -28.9% |
| Services [Member] | – | – | – | – | $7.53K | – | – | – | – | – | $0 | $0 | – | – |
By region
| Revenue | Q2 27 | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $437.51K | $433.40K | $400.61K | $346.06K | $614.92K | $667.43K | $642.38K | $645.80K | $442.83K | $408.53K | $524.61K | $427.84K | 100.0% | -28.9% |
| Foreign [Member] | – | – | $100 | $0 | $7.53K | – | – | – | – | – | – | – | – | – |
| Foreign [Member] | – | – | – | – | $7.63K | – | – | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of NutriBand's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.